A Biologics License Application for intismeran autogene will be submitted to the U.S. Food and Drug Administration by June 30, 2027. Merck will announce the filing and CBER will take charge of the review, leveraging the Breakthrough Therapy Designation that mRNA-4157/V940 earned in 2023. Moderna an…